The Demoucelle Parkinson Charity has announced that it will support a further four research projects aimed at finding a cure for Parkinson’s disease. These projects — selected together with The Michael J. Fox Foundation — are all based in Europe and focused on modifying the disease, rather than treating symptoms.
The Demoucelle Parkinson Charity applies the following selection criteria in choosing the projects to support:
— Disease-modifying therapeutics
— In pre-clinical development or beyond
— In Belgium and elsewhere in Europe
Board member and neuropharmacologist Dr. Ian Reynolds emphasised the important role that philanthropy plays in advancing Parkinson’s research.
”Donations directly impact research. Funding attracts scientists who in turn bring new ideas
and new techniques to Parkinson’s disease research. Funding can also determine which
aspects of the disease are investigated first or most. In this way, funding from donors
— whether large or small — can really advance and accelerate research.
More, better, faster – that is how philanthropy changes the course of research in Parkinson’s!”
—————————————
PROJECTS SUPPORTED
- Louise Klem and Anders Nykjaer, VesperBio, Denmark
–Examining the neuroprotective and anti-inflammatory effects of sortilin inhibition and progranulin elevation in rodent models of Parkinson’s Disease.
(Click here for more information.)
- Manuel Blanc, Lys Therapeutics, France
— Glunomab: a novel immunotherapy for the treatment of Parkinson’s Disease.
(Click here for more information.)
- Rodolphe Clerval, Coave Therapeutics, France
— Preclinical proof of concept of TFEB in Parkinson Disease.
(Click here for more information. Last updated in autumn 2023.)
- Philip Milliken, Galvani Bioelectronics Inc, UK
— Splenic nerve stimulation to reduce inflammation-driven Parkinson’s progression and LRRK2 mutation-driven Parkinson’s risk.
(Click here for more information.)
For more information on all the projects supported by DPC, click here.
Photo by Michael Longmire on Unsplash
